High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6

被引:84
作者
Xu, B
Broome, U
Ericzon, BG
Sumitran-Holgersson, S
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Immunol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Div Gastroenterol, S-14186 Huddinge, Sweden
关键词
D O I
10.1136/gut.51.1.120
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: Sera of patients with autoimmune liver diseases were investigated for the presence of autoantibodies binding to human biliary epithelial cells (BECs). Furthermore, their functional capacity was investigated by testing their capacity to fix complement as well as induce expression of various adhesion molecules and production of cytokines. Methods: Sera from patients with various stages of primary sclerosing cholangitis (PSC; n=30), primary biliary cirrhosis (PBC; n=29), autoimmune hepatitis (AIH; n=25), and normal controls (n=12) were investigated for the presence of antibodies that reacted with unstimulated and cytokine stimulated BECs isolated from a normal healthy liver. To demonstrate organ specificity, lung epithelial cells (LECs) were used as control cells. Antibodies were tested for their functional capacity. Results: Compared with controls (8%), significantly higher numbers of PSC patients (63%, p=0.001 but not PBC (37%, INS) or AIH (16%, INS) patients, had anti-BEC antibodies. In 90% of PSC patients, the autoantibodies reacted only with cytokine stimulated target cells. Lower numbers of PSC (6%), PBC (10%), and AIH (0%) patients had LEC antibodies. Other significant findings were that anti-BEC antibodies were found in (i) PSC patients with either the HLA-DRB1*0301 or DR2 allele compared with those without (p=0.007); and (ii) in PBC patients with end stage disease compared with those without (p=0.018). Furthermore, anti-BEC antibodies from PSC and PBC but not AIH patients induced BECs to produce high levels of the cytokine interleukin 6.1 muM and IgG fractions isolated from PSC but not PBC and AIH sera induced significantly increased expression of the cell adhesion molecule CD44. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis of BEC membranes demonstrated a specific band of 40 kDa with PSC sera and 45, 42, 30, and 33 kDa bands with PBC sera, which were absent in control groups. Conclusion: Thus for the first time we have demonstrated the presence of functionally important autoantibodies to cell surface expressed antigens on the relevant target cells of destruction, namely BECs, in PSC and PBC. These finding have important implications for the pathogenesis of bile duct destruction in these patients.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 40 条
[1]  
AADLAND E, 1987, SCAND J GASTROENTERO, V22, P655, DOI 10.3109/00365528709011139
[2]   Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis [J].
Bo, X ;
Broome, U ;
Remberger, M ;
Sumitran-Holgersson, S .
GUT, 2001, 49 (01) :131-141
[3]   ETIOLOGY AND PATHOGENESIS IN PRIMARY SCLEROSING CHOLANGITIS [J].
BOBERG, KM ;
LUNDIN, KEA ;
SCHRUMPF, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1994, 29 :47-58
[4]   Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].
Broome, U ;
Olsson, R ;
Loof, L ;
Bodemar, G ;
Hultcrantz, R ;
Danielsson, A ;
Prytz, H ;
SandbergGertzen, H ;
Wallerstedt, S ;
Lindberg, G .
GUT, 1996, 38 (04) :610-615
[5]  
CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530
[6]   Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis [J].
Cruickshank, SM ;
Southgate, J ;
Wyatt, JI ;
Selby, PJ ;
Trejdosiewicz, LK .
JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (10) :730-734
[7]  
DUERR RH, 1991, GASTROENTEROLOGY, V100, P1385
[8]   PRIMARY BILIARY-CIRRHOSIS - PARADIGM OR PARADOX FOR AUTOIMMUNITY [J].
GERSHWIN, ME ;
MACKAY, IR .
GASTROENTEROLOGY, 1991, 100 (03) :822-833
[9]   Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma - Validation of utility as a clinical marker [J].
Goydos, JS ;
Brumfield, AM ;
Frezza, E ;
Booth, A ;
Lotze, MT ;
Carty, SE .
ANNALS OF SURGERY, 1998, 227 (03) :398-404
[10]  
GUNTHERT U, 1995, CANCER SURV, V24, P19